1-(6-(methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway diseases

Abstract

To provide a pharmaceutical composition for treating inflammatory airway diseases.SOLUTION: The present invention relates to 1-(6-(methoxy)pyridazin-3-yl) cyclopropane-1-carboxamide derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IPF) or systemic sclerosis (SSc). The present description discloses exemplary compounds as well as relevant biological data thereof. An exemplary compound is e.g. N-(4-(7-acetyl-2,7-diazaspiro[3.5]nonan-2-yl)benzyl)-1-(6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide.SELECTED DRAWING: None

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to novel dapyridines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the treatment and / or prevention of diseases and disorders mediated by autotaxin. [Background technology]

[0002] 2. Background of the Invention Autotaxin (ATX; ENPP2) is a secreted enzyme responsible for hydrolyzing lysophosphatidylcholine (LPC) to the bioactive lipid lysophosphatidic acid (LPA) via its lysophospholipase D activity. LPA then exerts its effects by interacting with six GPCRs (LPA receptors 1-6, LPAR1-6) (Houben AJ, 2011). ATX-LPA signaling has been implicated in, for example, angiogenesis, chronic inflammation, autoimmune diseases, fibrotic diseases, cancer progression and tumor metastasis. For example, LPA acting on LPAR1 induces migration, proliferation and differentiation of lung fibroblasts; regulates epithelial and endothelial barrier function; and promotes lung epithelial cell apoptosis (Budd, 2013). ATX inhibition, LPAR1 gene deletion and selective LPAR1 antagonists have been shown to be effective in preclinical models of lung and skin fibrosis (Tager AM, 2008; Swaney J, 2010, Casetelino FV, 2016).

[0003] In patients with idiopathic pulmonary fibrosis (IPF), LPA levels are elevated in bronchoalveolar lavage fluid (Tager et al., 2008, Nat. Med.), elevated concentrations of ATX have been detected in human fibrotic lung tissue (Oikonomou et al., 2012, AJRCMB), LPA levels are elevated in exhaled breath condensate of IPF subjects (Montesi et al., 2014_BMCPM), and LPC is increased two-fold in serum of patients with stable IPF (Rindlisbacher et al., 2018, Resp. Res.). Thus, elevated ATX and / or LPA levels, altered LPA receptor expression, and altered responses to LPA may influence many pathophysiological conditions that are linked to ATX-LPA signaling.

[0004] Interstitial lung disease (ILD) is characterized by inflammation and fibrosis of the lung interstitium, the tissue and space between the air sacs (du Bois, Nat. Rev. Drug Discov. 2010, 9, 129-140). ILD can arise when injury to the lung triggers an abnormal healing response. ILD therefore includes progressive fibrotic interstitial lung disease (PFILD), where the response to lung injury becomes progressive and self-perpetuating, independent of the initial clinical association or trigger. The most prominent PFILDs are idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-ILD ​​(SSc-ILD). IPF is a chronic fibrotic, irreversible, and ultimately fatal lung disease characterized by progressive fibrosis in the pulmonary interstitium that reduces lung volume and leads to progressive pulmonary dysfunction. IPF is also characterized by a unique histopathological pattern known as usual interstitial pneumonia (UIP) (Raghu et al, Am. J. Respir. Crit. Care Med. 183: 788-824).

[0005] Systemic sclerosis (SSc), also called scleroderma, is an immune-mediated rheumatic disease of complex etiology. It is a multiorgan heterogeneous disease characterized by extensive fibrosis, vasculopathy and autoantibodies against various cellular antigens, with a high mortality rate. It is a rare disorder, i.e., an incurable disease with a high unmet need. Early clinical signs of SSc can be diverse. Raynaud's phenomenon and gastroesophageal reflux are often present early in the disease (Rongioletti F, et al., J Eur Acad Dermatol Venereol 2015; 29: 2399-404). Some patients present with inflammatory skin disease, puffy, swollen fingers, musculoskeletal inflammation, or constitutional signs, such as fatigue. Excessive collagen deposition in the skin of patients makes it thick and tough. In some patients, organ-based signs of the disease such as pulmonary fibrosis, pulmonary arterial hypertension, renal failure, or gastrointestinal complications are observed. Furthermore, one of the most common signs of immune involvement is the presence of abnormal levels of autoimmune antibodies (antinuclear antibodies or ANA) against the nuclei of one's own cells, which is seen in almost everyone with SSc (Guiducci S et al., Isr Med Assoc J 2016; 18: 141-43). ILD and pulmonary arterial hypertension (PAH) are the most frequent causes of death in SSc patients (Tyndall AJ et al. Ann Rheum Dis 2010; 69: 1809-15).

[0006] SSc patients are classified into two major disease subsets: diffuse cutaneous sclerosing systemic sclerosis and localized cutaneous sclerosing systemic sclerosis (LeRoy EC, et al., J Rheumatol 1988; 15:202-5). Three clinical features emerge, namely, excessive fibrosis (scarring), vasculopathy, and autoimmunity, and underlie the process that leads to the various manifestations that characterize SSc. SSc is currently considered a manifestation of dysregulated or dysfunctional repair of connective tissue to injury (Denton CP et al., Lancet 2017; 390: 1685-99). It would therefore be desirable to provide potent ATX inhibitors. Various structural classes of ATX inhibitors are reviewed in D. Castagna et al. (J.Med.Chem. 2016, 59, 5604-5621). WO2014 / 139882 discloses compounds that are ATX inhibitors having the following generalized structural formula:

[0007] [ka]

[0008] Example 2 therein is further disclosed by N. Desroy, et al. (J.Med.Chem. 2017, 60, 3580-3590, as Example 11) as a first-in-class ATX inhibitor undergoing clinical evaluation for the treatment of idiopathic pulmonary fibrosis. C. Kuttruff, et al. (ACS Med. Chem. Lett. 2017, 8, 1252-1257) discloses the ATX inhibitor BI-2545 (Example 19) that significantly reduces LPA levels in vivo. Summary of the Invention

[0009] Detailed Description of the Invention The present invention is surprisingly a potent inhibitor of autotaxin (Assay A) and further - high potency in human whole blood (Assay B), and - A significant reduction in plasma levels of LPA in vivo over a period of several hours (Assay C) The present invention provides a novel pyridazine having the following characteristics: The compounds of the present invention are useful as drugs for the treatment or prevention of diseases or conditions in which ATX activity and / or LPA signaling is involved, and which are involved in the etiology or pathology of the disease or are otherwise associated with at least one symptom of the disease. ATX-LPA signaling has been implicated in, for example, angiogenesis, chronic inflammation, autoimmune diseases, fibrotic diseases, cancer progression and tumor metastasis.

[0010] The compounds of the present invention exhibit the following parameters: - Efficacy as an ATX inhibitor, - Potency as an ATX inhibitor in human whole blood; -Reduce plasma levels of LPA in vivo for several hours The combination of ATX is a soluble plasma protein that is active in heparinized whole blood. Its substrate LPC is present in very large amounts, with concentrations in the μM range. Therefore, whole blood assays at physiological substrate concentrations are highly relevant assays to predict the efficacy of ATX inhibitors in vivo.

[0011] In vivo LPA reduction is determined by measuring plasma concentrations of LPA following oral administration of the compounds of the invention. LPA is a highly bioactive lipid that efficiently activates downstream pathways in a concentration-dependent manner via LPA receptors 1-6. A clear and sustained blockade of LPA formation via ATX inhibition is assayed by measuring the extent of LPA reduction 8 hours after compound administration. Thus, the large reduction in plasma LPA at 8 hours is highly indicative of sustained target engagement of LPA receptors as well as efficacy and duration of action in vivo. The compounds of the present invention are structurally distinct from Examples 2 and 12 of WO2014 / 139882 and Example 19 of ACS Med. Chem. Lett. 2017, 8, 1252-1257, i.e., the compounds of the present invention contain a central pyridazine core with substituents at positions 3 and 6. This structural difference unexpectedly results in a superior combination of (i) inhibition of ATX, (ii) inhibition of ATX in human whole blood, and (iii) reduction of plasma concentration levels of LPA in vivo over several hours. As a result, compounds of the invention exhibit high in vivo target engagement and can be predicted to have greater efficacy in humans. The present invention provides novel compounds of formula (I):

[0012] [ka] (I)

[0013] During the ceremony, A is fluoro and F 1-7 -Fluoro-C 1-3 -pyridyl substituted with one or two members of the group consisting of alkyl; E is fluoro and F 1-7 -Fluoro-C 1-3 - selected from the group consisting of phenyl and pyridyl, optionally substituted with one or two members of the group consisting of alkyl; K is the following group

[0014] [ka]

[0015] selected from the group consisting of; R 3 is R 4 (O)C-, methyl, and

[0016] [ka]

[0017] selected from the group consisting of; R 4 is methyl.

[0018] Another embodiment of the invention is where A is one or two F. 1-3 -fluoro-C1-alkyl substituted pyridyl; and the substituents E and K are as defined in the preceding embodiments. Another embodiment of the invention relates to compounds of formula (I) wherein A is pyridyl substituted with one or two members of the group consisting of F2HC, and F3C; and the substituents E and K are as defined in the preceding embodiments. Another embodiment of the present invention is where A is

[0019] [ka]

[0020] selected from the group consisting of; and the substituents E and K are as defined in any of the preceding embodiments. Another embodiment of the present invention is wherein E is selected from the group consisting of phenyl and pyridyl, optionally substituted with one or two members of the group consisting of F and F3C; and the substituents A and K are as defined in any of the preceding embodiments. Another embodiment of the present invention is where E is the group

[0021] [ka]

[0022] selected from the group consisting of; and the substituents A and K are as defined in any of the preceding embodiments. According to the invention, preferably the compound of formula (I) is selected from the group consisting of the following compounds:

[0023] [ka]

[0024] [ka]

[0025] [ka]

[0026] [ka]

[0027] A further embodiment relates to a pharmaceutical composition comprising at least one compound of formula I of the present invention or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients. A further embodiment relates to a compound of formula (I) of the present invention for use as a medicament. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] Terms and definitions used Terms not specifically defined herein are to be given the meaning that one of ordinary skill in the art would give them in light of the present disclosure and the context. However, as used herein, unless otherwise specified, the following terms have the indicated meanings and adhere to the following conventions. In the groups, radicals, or moieties below, the number of carbon atoms is often specified preceding the group, e.g., C 1-6 -Alkyl means an alkyl group having 1 to 6 carbon atoms. In general, for groups such as HO, H2N, (O)S, (O)2S, NC (cyano), HOOC, F3C, etc., the point of attachment of the group to the molecule would be known to one skilled in the art from the free valence of the group itself. For combination groups containing two or more subgroups, the last named subgroup is the point of attachment of the group, e.g., the substituent "aryl-C 1-3 -alkyl" is C 1-3 - means an aryl group bonded to an alkyl group, where the alkyl group is bonded to the core or group to which the substituent is attached. When the compounds of the invention are depicted in the form of chemical names and as chemical formulas, the formulas shall prevail in the event of any discrepancies. An asterisk may be used in subformulas to indicate a bond that is attached to the core molecule as defined. The numbering of substituent atoms begins with the atom closest to the core or group to which the substituent is attached. For example, the term "3-carboxypropyl" represents the following substituent:

[0029] [ka]

[0030] wherein the carboxy group is attached to the third carbon atom of the propyl group. The term "1-methylpropyl-", "2,2-dimethylpropyl-" or "cyclopropylmethyl-" represents the following group:

[0031] [ka]

[0032] An asterisk may be used in a subformula to represent a bond that is attached to the core molecule as defined. As used herein, the term "substituted" means that any one or more hydrogens on the designated atom are replaced with a selection from the indicated group, provided that the normal valence of the designated atom is not exceeded and such substitution results in a stable compound. The term "C", alone or in combination with other groups, 1-n "-alkyl" (n is an integer selected from 2, 3, 4, 5 or 6, preferably 4 or 6) means an acyclic saturated branched or straight chain hydrocarbon group having 1 to n C atoms. For example, the term C 1-5 -Alkyl is the group H3C-, H3C-CH2-, H3C-CH2-CH2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C- CH2-CH(CH3)-, H3C-CH(CH3)-CH2-, H3C-C(CH3)2-, H3C-CH2-CH2-CH2-CH2-, H3C-C Includes H2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH(CH3)-CH2-CH2-, H3C-CH2-C(CH3)2-, H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)- and H3C-CH2-CH(CH2CH3)-. The term "halogen" refers to chlorine, bromine, iodine, and fluorine. The term "halo" added to an "alkyl", "alkylene" or "cycloalkyl" group (saturated or unsaturated) refers to an alkyl or cycloalkyl group having one or more hydrogen atoms replaced by a halogen atom selected from among fluorine, chlorine or bromine, preferably fluorine and chlorine, and particularly preferably fluorine. Examples include H2FC-, HF2C-, F3C-. The term phenyl refers to the following ring radical:

[0033] [ka]

[0034] The term pyridinyl refers to the following ring radical:

[0035] [ka]

[0036] The term pyridazine refers to the ring:

[0037] [ka]

[0038] Unless specifically indicated, throughout this specification and the appended claims, a given chemical formula or name is intended to encompass tautomers and all stereo, optical, and geometric isomers (e.g., enantiomers, diastereomers, E / Z isomers, etc.) and racemates thereof as well as mixtures of different ratios of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the aforementioned forms in which said isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts, and solvates thereof, including, for example, solvates of the free compounds or solvates of a salt of the compound. In general, substantially pure stereoisomers can be obtained according to synthetic principles known to those skilled in the art, for example by separation of corresponding mixtures, by the use of stereochemically pure starting materials and / or by stereoselective synthesis. It is well known in the art how to prepare optically active forms, for example by resolution of racemic forms or by synthesis starting from, for example, optically active starting materials and / or by the use of chiral reagents.

[0039] Enantiomerically pure compounds or intermediates of the present invention may be prepared via asymmetric synthesis, for example by subsequent separation of suitable diastereomeric compounds or intermediates which can be separated by known methods (e.g. chromatographic separation or crystallization) and / or by using chiral reagents, such as chiral starting materials, chiral catalysts or chiral auxiliaries. Furthermore, the skilled artisan knows how to prepare enantiomerically pure compounds from the corresponding racemic mixtures, such as, for example, by chromatographic separation of the corresponding racemic mixtures on chiral stationary phases; or by resolution of the racemic mixtures with a suitable resolving agent, for example by formation of diastereomeric salts of the racemates with an optically active acid or base, followed by separation of the salts and liberation of the desired compound from the salt; or by derivatization of the corresponding racemate with an optically active chiral auxiliary reagent, followed by diastereomeric separation and removal of the chiral auxiliary; or by kinetic resolution of the racemates (for example enzymatic resolution); by enantioselective crystallization under suitable conditions from a conglomerate of mirror image crystals; or by (fractional) crystallization from a suitable solvent in the presence of an optically active chiral auxiliary.

[0040] The phrase "pharmacologically acceptable" is used herein to refer to those compounds, substances, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use without undue toxicity, irritation, allergic response, or other problem or complication and commensurate with a reasonable benefit / risk ratio. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds where the parent compound forms salts or complexes with acids or bases. Examples of acids that form pharma- ceutically acceptable salts with the parent compound that contains a basic moiety include mineral or organic acids, such as benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid, and tartaric acid.

[0041] Examples of cations and bases that form pharma- ceutical acceptable salts with the parent compound that contains an acidic moiety include Na + , K + , Ca 2+ , Mg 2+ , NH4 + , L-arginine, 2,2'-iminobisethanol, L-lysine, N-methyl-D-glucamine or tris(hydroxymethyl)-aminomethane. The pharma- ceutically acceptable salts of the present invention can be synthesized from a parent compound that contains an acidic or basic moiety by conventional chemical methods. Generally, the salts can be prepared by reacting the free acid or base form of these compounds with a sufficient amount of the appropriate base or acid in water or an appropriate organic diluent such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof. Salts of acids other than those mentioned above, which are useful, for example, for purifying or isolating the compounds of the invention (eg, trifluoroacetates), also form part of the invention.

[0042] Biological assays The biological activity of the compounds was determined by the following methods. Assay A: Biochemical ATX assay 50 mM Tris buffer (pH 8.0) containing 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.14 mM NaCl, and 0.1% bovine serum albumin was supplemented with 5 nM recombinant ATX (Cayman Chemicals). Test compounds were dissolved in DMSO and tested in the range of 0.1 nM to 10 μM. The enzymatic reaction (22.5 μL) was initiated by the addition of 2.5 μL of 10 μM 18:1 LPC (Avanti Lipids, Alabaster, AL, USA). After 2 h of incubation at room temperature, the reaction was stopped by the addition of 20 μL of water containing 500 nM 20:4 LPA as an internal standard and 100 μL of 1-butanol to extract LPA. The plate was subsequently centrifuged at 4000 rpm for 2 min at 4 °C. The resulting upper butanol phase was used directly for injection on a RapidFire system (Agilent).

[0043] A RapidFire autosampler was coupled to a binary pump (Agilent 1290) and a Triple Quad 6500 (ABSciex, Toronto, Canada). The system was equipped with a 10 μL loop, a 5 μL Waters Atlantis HILIC cartridge (Waters, Elstree, UK), 90% acetonitrile containing 10 mM ammonium acetate as eluent A and 40% acetonitrile containing 10 mM ammonium acetate as eluent B. For details, see below (Bretschneider et al., SLAS Discovery, 2017). One MS was operated in negative mode with a source temperature of 550 °C, curtain gas = 35, gas 1 = 65, and gas 2 = 80. The following transition and MS parameters (DP: declustering potential and CE: collision energy) were determined for each LPA: 18:1 LPA 435.2 / 152.8, DP=-40, CE=-28 and 20:4 LPA 457.2 / 152.8, DP=-100, CE=-27). The formation of 18:1 LPA was monitored and assessed as a ratio to 20:4 LPA.

[0044] Table 1: Biological data of compounds of the invention obtained by Assay A [Table 1]

[0045] Table 2: Biological data of prior art compounds (Examples 2 and 12 of WO2014 / 139882) obtained in Assay A [Table 2]

[0046] Table 3: Biological data of a prior art compound (Example 19 of ACS Med. Chem. Lett. 2017, 8, 1252-1257) obtained in Assay A [Table 3]

[0047] Assay B: Whole blood ATX assay 5 μL of test compound (concentration range: 0.12 nM-100 μM) dissolved in phosphate-buffered saline was supplemented to 45 μL of human whole blood. The mixture was incubated for 1 h at 37 °C and stopped by the addition of 100 μL of 40 mM disodium hydrogen phosphate buffer containing 30 mM citric acid (pH 4) and 1 μM 17:0 LPA (internal standard). LPA was extracted by the addition of 500 μL of 1-butanol, followed by centrifugation at 4000 rpm and 4 °C for 10 min. From the resulting organic supernatant, 200 μL aliquots were transferred to a 96-deep-well plate and transferred to RapidFire-based MS / MS measurements. A RapidFire autosampler was coupled to a binary pump (Agilent 1290) and a Triple Quad 6500 (ABSciex, Toronto, Canada). The system was equipped with a 10 μL loop, a 5 μL Waters Atlantis HILIC cartridge (Waters, Elstree, UK), 90% acetonitrile containing 10 mM ammonium acetate as eluent A and 40% acetonitrile containing 10 mM ammonium acetate as eluent B. See below for details (Bretschneider et al., SLAS Discovery, 2017, 22, 425-432). The MS was operated in negative mode with a source temperature of 550 °C, curtain gas = 35, gas 1 = 65, and gas 2 = 80. The following transitions and MS parameters (DP: declustering potential and CE: collision energy) were determined for each LPA: 18:2 LPA 433.2 / 152.8, DP=-150, CE=-27 and 17:0 LPA 423.5 / 152.8, DP=-100. The formation of 18:2 LPA was monitored and assessed as a ratio to 17:0 LPA.

[0048] Table 4: Biological data of compounds of the invention obtained in Assay B [Table 4]

[0049] Table 5: Biological data of prior art compounds (Examples 2 and 12 of WO2014 / 139882) obtained in Assay B [Table 5]

[0050] Table 6: Biological data of the prior art compound (Example 19 of ACS Med. Chem. Lett. 2017, 8, 1252-1257) obtained in Assay B [Table 6]

[0051] Assay C: In vivo Test substances were solubilized in 0.5% natrosol supplemented with 0.015% Tween 80 for oral administration to rats at a dose of 5 mg / kg. Blood samples were taken before compound administration and 8 hours after administration on ice using EDTA as a coagulant. Plasma was subsequently prepared by centrifugation and stored at -20°C until analysis. LPA from plasma samples was extracted using the procedure described by Scherer et al. (Clinical chemistry 2009, 55, 1218-22). 35 μL of heparinized plasma was mixed with 200 μL of 40 mM disodium hydrogen phosphate buffer containing 30 mM citric acid (pH 4) and 1 μM 17:0 LPA (internal standard). Subsequently, 500 μL of butanol was added and shaken vigorously for 10 min. The samples were then centrifuged at 4000 rpm and 4 °C for 10 min. 500 μL of the organic upper phase was transferred to a fresh 96-deep well plate and centrifuged at 15 psi (1.03 × 10 5 The mixture was evaporated with a gentle stream of nitrogen at 1000 psi (2 Pa) for 45 min. The resulting residue was dissolved in 100 μL of ethanol before LC-MS analysis.

[0052] LC-MS methods for the analysis of in vivo samples A Triple Quad 6500 (ABSciex, Toronto, Canada) was equipped with an Agilent 1290 LC system (Agilent, Santa Clara, CA), a CTC autosampler, and an Atlantis 50 × 2.1 mm, 3 μm HILIC LC column (Waters, Elstree, UK). Eluent A contained 0.2% formic acid and 50 mM ammonium formate in water, while eluent B consisted of 0.2% formic acid in acetonitrile. The LC gradient started with 95% solvent B, reduced to 75% within 1.5 min and 50% solvent B within 0.2 min, and then diluted from 500 to 700 μL·min -1 At 1.8 min, solvent B was changed back to 95% and held constant for 0.7 min to re-equilibrate the column. The following LPA species were monitored (DP: declustering potential and CE: collision energy): 16:0 LPA 409.2 / 152.8, DP=-150, CE=-28; 18:0 LPA 437.3 / 152.8, DP=-60, CE=-28; 18:1 LPA 435.2 / 152.8, DP=-40, CE=-28; 18:2 LPA 433.2 / 152.8, DP=-150, CE=-28; 20:4 LPA 457.2 / 152.8, DP=-100, CE=-29 and 17:0 LPA 423.5 / 152.8, DP=-100, CE=-36. Percent LPA reduction was calculated based on baseline LPA levels prior to test compound application. Total LPA refers to the species 16:0; 18:0; 18:1; 18:2 and 20:4.

[0053] Table 7: Biological data of compounds of the invention obtained in Assay C [Table 7]

[0054] Table 8: Biological data of prior art compounds (Examples 2 and 12 of WO2014 / 139882) obtained in Assay C [Table 8]

[0055] Table 9: Biological data of the prior art compound (Example 19 of ACS Med. Chem. Lett. 2017, 8, 1252-1257) obtained in Assay C [Table 9]

[0056] Treatment method The present invention relates to compounds of general formula (I) useful for the prevention and / or treatment of diseases and / or conditions associated with or modulated by the physiological activity of ATX and / or LPA, such as, but not limited to, inflammatory conditions, fibrotic diseases, respiratory conditions, renal conditions, hepatic conditions, vascular and cardiovascular conditions, cancer, ophthalmic conditions, metabolic conditions, cholestatic and other forms of chronic pruritus, as well as acute and chronic organ transplant rejection and neurological conditions.

[0057] Compounds of general formula (I) are useful in treating inflammatory conditions, including but not limited to Sjogren's syndrome, arthritis, osteoarthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD) and chronic asthma; fibrotic diseases, including but not limited to interstitial lung diseases (ILD), such as progressive fibrotic interstitial lung disease (PFILD), such as idiopathic pulmonary fibrosis (IPF), and SSC-ILD, familial interstitial lung disease, myocardial and vascular fibrosis, renal fibrosis, hepatic fibrosis, pulmonary fibrosis, skin fibrosis, collagen vascular diseases such as systemic sclerosis (SSc) and encapsulating peritonitis. respiratory conditions, including but not limited to diffuse parenchymal lung diseases of various etiologies, such as iatrogenic drug-induced fibrosis, occupational and / or environmental induced fibrosis, systemic diseases and vasculitis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), renal conditions, including but not limited to end stage renal disease (ESRD), focal segmental glomerulosclerosis, IgA nephropathy, vasculitis / systemic diseases, and acute and chronic renal transplant rejection, with and without proteinuria; hepatic conditions, including but not limited to cirrhosis, hepatic congestion, cholestatic liver disease, such as pruritus, primary biliary cholangitis, nonalcoholic steatohepatitis, and acute and chronic liver transplant rejection; vascular conditions, including but not limited to atherosclerosis, arteriosclerosis, thrombotic vascular disease and thrombotic microangiopathy, proliferative arteriopathy (e.g., swollen myointimal cells and nodular thickening surrounded by a mucous extracellular matrix), endothelial dysfunction, etc.; cardiovascular conditions, such as, but not limited to, acute coronary syndromes, coronary heart disease, myocardial infarction, arterial pulmonary hypertension, arrhythmias such as atrial fibrillation, stroke and other vascular injuries, etc.; cancer and cancer metastasis, such as, but not limited to, breast cancer, ovarian cancer, lung cancer, prostate cancer, mesothelioma, glioma, liver cancer, gastrointestinal cancer and their progressive and metastatic aggressiveness, etc.; ophthalmic conditions, such as, but not limited to, proliferative and non-proliferative (diabetic) retinopathy, dry and wet age-related macular degeneration (AMD), macular edema, central arterial / venous occlusion, trauma, glaucoma, etc.; metabolic conditions, such as, but not limited to, obesity, dyslipidemia and diabetes, etc.;They are useful in the prevention and / or treatment of conditions of the nervous system, including but not limited to neuropathic pain, Alzheimer's disease, schizophrenia, neuroinflammation (e.g., astrogliosis), peripheral and / or autonomic (diabetic) neuropathy, etc.;

[0058] Thus, the present invention relates to compounds of general formula (I) for use as medicaments. Furthermore, the present invention relates to the use of compounds of general formula (I) for the treatment and / or prevention of diseases and / or conditions associated with or modulated by the physiological activity of ATX and / or LPA. Furthermore, the present invention relates to the use of compounds of general formula (I) for the treatment and / or prevention of diseases and / or conditions associated with or modulated by the physiological activity of ATX and / or LPA, such as, but not limited to, inflammatory conditions, fibrotic diseases, respiratory conditions, renal conditions, hepatic conditions, vascular and cardiovascular conditions, cancer, ophthalmic conditions, metabolic conditions, cholestatic and other forms of chronic pruritus, as well as acute and chronic organ transplant rejection and neurological conditions.

[0059] Further, the present invention relates to the treatment of inflammatory conditions, including, but not limited to, Sjogren's syndrome, arthritis, osteoarthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, inflammatory airway diseases, such as chronic obstructive pulmonary disease (COPD) and chronic asthma; fibrotic diseases, including, but not limited to, interstitial lung diseases (ILD), such as progressive fibrotic interstitial lung diseases (PFILD), such as idiopathic pulmonary fibrosis (IPF), and SSC-ILD, familial interstitial lung disease, myocardial and vascular fibrosis, renal fibrosis, hepatic fibrosis, pulmonary fibrosis, skin fibrosis, collagen vascular diseases, such as systemic sclerosis (SSc) and encapsulating peritonitis. respiratory conditions, including but not limited to diffuse parenchymal lung diseases of various etiologies, such as iatrogenic drug-induced fibrosis, occupational and / or environmental induced fibrosis, systemic diseases and vasculitis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), renal conditions, including but not limited to end stage renal disease (ESRD), focal segmental glomerulosclerosis, IgA nephropathy, vasculitis / systemic diseases, and acute and chronic renal transplant rejection, with and without proteinuria; hepatic conditions, including but not limited to cirrhosis, hepatic congestion, cholestatic liver disease, such as pruritus, primary biliary cholangitis, nonalcoholic steatohepatitis, and acute and chronic liver transplant rejection; vascular conditions, including but not limited to atherosclerosis, arteriosclerosis, thrombotic vascular disease and thrombotic microangiopathy, proliferative arteriopathy (e.g., swollen myointimal cells and nodular thickening surrounded by a mucous extracellular matrix), endothelial dysfunction, etc.; cardiovascular conditions, such as, but not limited to, acute coronary syndromes, coronary heart disease, myocardial infarction, arterial pulmonary hypertension, arrhythmias such as atrial fibrillation, stroke and other vascular injuries, etc.; cancer and cancer metastasis, such as, but not limited to, breast cancer, ovarian cancer, lung cancer, prostate cancer, mesothelioma, glioma, liver cancer, gastrointestinal cancer and their progressive and metastatic aggressiveness, etc.; ophthalmic conditions, such as, but not limited to, proliferative and non-proliferative (diabetic) retinopathy, dry and wet age-related macular degeneration (AMD), macular edema, central arterial / venous occlusion, trauma, glaucoma, etc.; metabolic conditions, such as, but not limited to, obesity, dyslipidemia and diabetes, etc.;The present invention relates to the use of compounds of general formula (I) for the treatment and / or prevention of conditions of the nervous system, such as, but not limited to, neuropathic pain, Alzheimer's disease, schizophrenia, neuroinflammation (e.g. astrogliosis), peripheral and / or autonomic (diabetic) neuropathy;

[0060] In a further aspect the present invention relates to the compounds of general formula (I) for use in the treatment and / or prevention of the abovementioned diseases and conditions. In a further aspect, the present invention relates to the use of compounds of general formula (I) for the preparation of a medicament for the treatment and / or prevention of the abovementioned diseases and conditions. In a further aspect, the present invention relates to a method for the treatment or prevention of the above mentioned diseases and conditions, which comprises the administration to a human of an effective amount of a compound of general formula (I).

[0061] Pharmaceutical Compositions Suitable formulations for administration of a compound of formula (I) will be apparent to those skilled in the art and include, for example, tablets, pills, capsules, suppositories, lozenges, troches, liquids, syrups, elixirs, sachets, injectables, inhalants and powders. Suitable tablets can be obtained, for example, by mixing one or more compounds of formula I with known excipients, such as inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and / or lubricants.

[0062] Combination therapy The compound of the present invention can be used in combination with other treatment options known in the art to treat the indications for which the present invention is useful, using at least two active compounds in effective amounts at the same time.Combination therapy preferably includes administering two active compounds to a patient at the same time, but the compounds do not have to be administered to a patient at the same time, although effective amounts of each compound will be present in the patient at the same time.The compound of the present invention may be administered with one or more combination partners as described elsewhere herein. Thus, the present invention provides a compound of formula (I) according to any of the above embodiments, characterized in that the compound of formula (I) is administered in addition to a treatment with one or more anti-inflammatory molecules from the list consisting of an IL6 modulator, an anti-IL6R modulator and an IL13 / IL-4 JAKi modulator.

[0063] According to another aspect, the invention provides a compound of formula (I) according to any of the previous embodiments, characterized in that the compound of formula (I) is administered in addition to a treatment with one or more anti-fibrotic molecules from the list consisting of CB2 agonists, TGF modulators, FGFR modulators, VEGFR inhibitors, PDGFR inhibitors, FGF modulators, αvβ6 integrin modulators, anti-CTGF antibodies, ROCK2 inhibitors, rhPTX-2 (Pentraxin-2), JNK1 inhibitors, LOXL2 inhibitors, Galectin 3 inhibitors, MK2 inhibitors, Wnt pathway inhibitors, TGFR inhibitors, PDE4 modulators, TRPA1 inhibitors and microRNA modulators. According to another aspect, the invention provides a compound of formula (I) according to any of the preceding embodiments, characterized in that the compound of formula (I) is administered in addition to nintedanib. According to another aspect, the invention provides a compound of formula (I) according to any of the preceding embodiments, characterized in that the compound of formula (I) is administered in addition to pirfenidone.

[0064] preparation The compounds of the invention can be obtained using synthetic methods known to those skilled in the art and described in the organic synthesis literature. It is preferred to obtain the compounds similarly to the preparation methods described more fully below, in particular as described in the experimental section. The general process for preparing the compounds of the present invention will be apparent to those skilled in the art upon studying the schemes below. The starting materials may be prepared by methods described in the literature or herein, or in a similar or analogous manner. Any functional group of the starting materials or intermediates may be protected using conventional protecting groups. These protecting groups may be cleaved again at an appropriate stage in the reaction sequence using methods familiar to those skilled in the art. Compounds of general formula (I) may be prepared by amide coupling of amines (VII) with acids (VI).

[0065] [ka]

[0066] Saponification of ester (VI) (R is a suitable acid protecting group, e.g., methyl or ethyl) gives acid (VII). Ester (VI) is prepared by coupling benzyl alcohol (V) to halide (IV) using a base where X is a halogen such as Cl, Br or I. Ester (IV) can be synthesized by alkylation of halopyridazine (II) with alkyl halide (III) where Y is a halogen such as Cl, Br or iodine.

[0067] [ka]

[0068] [ka] EXAMPLES

[0069] Experimental Part The following examples are intended to illustrate the invention without limiting it. The terms "ambient temperature" and "room temperature" are used interchangeably to designate a temperature of about 20°C.

[0070] [Table 10] TIFF0007617165000029.tif208158 TIFF0007617165000030.tif135158

[0071] Preparation of starting compounds Example I Example I.1 4-(4-Acetylpiperazin-1-yl)-3-fluorobenzonitrile

[0072] [ka]

[0073] To a solution of 0.40 g (1.95 mmol) 3-fluoro-4-piperazin-1-yl-benzonitrile (CAS-No. 182181-38-0) and 0.60 ml (4.30 mmol) triethylamine in 7 mL DCM, 0.14 mL (1.95 mmol) acetyl chloride is added and the mixture is stirred overnight at RT. The reaction mixture is treated with 0.09 mL (1.25 mmol) triethylamine and stirred for 2 h at RT. The organic layer is washed with water, dried over PTK and the solvent is evaporated under reduced pressure to give 500 mg of crude product. C 13 H 14 FNO (M = 247.3 g / mol) ESI-MS: 248 [M+H] + R t (HPLC): 0.82 min (Method B) Following the general procedure above (Example I.1) the following compounds are prepared:

[0074] [ka] TIFF0007617165000033.tif139163

[0075] Example II Example II.1 1-{4-[4-(aminomethyl)-2-fluorophenyl]piperazin-1-yl}ethan-1-one

[0076] [ka]

[0077] A mixture of 550 mg (2.22 mmol) of 4-(4-acetylpiperazin-1-yl)-3-fluorobenzonitrile (Example I.1), 55.0 mg of Raney nickel and 15 mL of 7N ammonia in MeOH was heated under a hydrogen atmosphere (50 psi (3.4 × 10 5 Stir at 50° C. and below 10 Pa overnight, filter, and reduce in vacuo to give 510 mg of product. C 13 H 18 FNO (M = 251.3 g / mol) ESI-MS: 252 [M+H] + R t (HPLC): 0.68 min (Method A) The following compounds are prepared according to the above general procedure (Example II.1):

[0078] [ka] TIFF0007617165000036.tif203165 TIFF0007617165000037.tif82163

[0079] Example III Example III.1 4-(4-Acetylpiperazin-1-yl)-2-fluorobenzonitrile

[0080] [ka]

[0081] A mixture of 0.50 g (2.50 mmol) of 4-bromo-2-fluorobenzonitrile (CAS-No. 105942-08-3), 0.32 g (2.50 mmol) of 1-(piperazin-1-yl)ethan-1-one (CAS-No. 13889-98-0), 1.63 g (5.00 mmol) of cesium carbonate and 0.05 g (0.06 mmol) of XPhos Pd G3 (CAS-No. 1445085-55-1) in 2 mL of 1,4-dioxane is stirred at 80 ° C overnight. It is diluted with water. The remaining solid is filtered, washed with water and dried under air atmosphere to give 570 mg of product. C 13 H 14 FNO (M = 247.3 g / mol) ESI-MS: 248 [M+H] + R t (HPLC): 0.79 min (Method A) The following compounds are prepared according to the above general procedure (Example III.1):

[0082] [ka]

[0083] Example IV Example IV.1 4-{6-methyl-7-oxo-2,6-diazaspiro[3.4]octan-2-yl}benzonitrile

[0084] [ka]

[0085] 222 mg (1.81 mmol) of 4-fluorobenzonitrile (CAS No. 1194-02-1) and 320 mg (1.81 mmol) of 6-methyl-2,6-diazaspiro[3.4]octan-7-one hydrochloride (CAS No. 2097951-61-4) diluted in 1.6 mL of DMSO are treated with 790 mg (5.62 mmol) of K2CO3 and stirred at 120 °C for 3 h and at RT overnight. The reaction mixture is cooled and diluted with water. The precipitate is filtered, washed with water and dried in vacuum at 50 °C to give 340 mg of product. C 14 H 15 NO (M = 241.3 g / mol) ESI-MS: 242 [M+H] + R t (HPLC): 0.79 min (Method B) The following compounds are prepared according to the above general procedure (Example IV.1):

[0086] [ka] TIFF0007617165000042.tif197145 TIFF0007617165000043.tif177142

[0087] [Table 11]

[0088] Example V Example V.1 4-{2,7-diazaspiro[3.5]nonan-2-yl}benzonitrile; Trifluoroacetic acid

[0089] [ka]

[0090] 255 mg (0.780 mmol) of tert-butyl 2-(4-cyanophenyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (Example IV.2) are diluted with 5 mL of DCM and 300 μL (3.89 mmol) of TFA are added. The reaction mixture is stirred at RT for 2 h and concentrated under reduced pressure to give 260 mg of product. C 14 H 17 N3 * C2HF3O2 (M=341.3 g / mol) ESI-MS: 228 [M+H] + R t (HPLC): 0.69 min (Method B) The following compounds are prepared according to the above general procedure (Example V.1):

[0091] [ka] TIFF0007617165000047.tif109159

[0092] Example VI 4-{2,6-diazaspiro[3.3]heptan-2-yl}benzonitrile

[0093] [ka]

[0094] A solution of 0.90 g (3.01 mmol) of tert-butyl 6-(4-cyanophenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (Example IV.3) in 8 mL of ACN is treated with 1.14 g (6.01 mmol) of p-toluenesulfonic acid monohydrate and stirred at RT for 24 h. The reaction mixture is diluted with DCM and extracted with saturated NaHCO3 solution. The combined organic layers are diluted with MgSO4 and concentrated under reduced pressure to give 600 mg of product. C 12 H 13 N3 (M = 199.3 g / mol) ESI-MS: 200 [M+H] + R t (HPLC): 0.62 min (Method B)

[0095] Example VII 1-(6-chloropyridazin-3-yl)cyclopropane-1-carboxylate ethyl

[0096] [ka]

[0097] A solution of 13.8 g (68.8 mmol) of ethyl 2-(6-chloropyridazin-3-yl)acetate (CAS No. 1023817-10-8) in 100 mL of DMSO is cooled in an ice bath and treated with 8.25 g (206.4 mmol) of sodium hydride (60% dispersion). The reaction mixture is stirred for 20 min. 8.89 mL (103.2 mmol) of dibromoethane is added to the reaction mixture and stirred for 45 min under temperature control (max. 38 °C). The reaction mixture is cooled in ice and diluted with NH4Cl solution. The aqueous phase is extracted with EtOAc. The combined organic layers are dried over MgSO4 and concentrated under reduced pressure. The residue is purified by column chromatography (silica gel; eluent: Cy / EtOAc = 90 / 10 → 65 / 35) to give 11.4 g of product. C 10 H 11 ClNO2O2 (M = 226.7 g / mol) ESI-MS: 227 [M+H] + R t (HPLC): 0.86 min (Method B)

[0098] Example VIII Example VIII.1 1-(6-{[6-(difluoromethyl)pyridin-3-yl]methoxy}pyridazin-3-yl)cyclopropane-1-carboxylic acid

[0099] [ka]

[0100] 843 mg (5.29 mmol) of [6-(difluoromethyl)pyridin-3-yl]methanol (CAS No. 946578-33-2) in 8 mL of DMF are cooled in an ice bath and 385 mg (8.82 mmol) of sodium hydride (55% purity) are added. The mixture is stirred at RT for 10 min. 1.00 g (4.41 mmol) of ethyl 1-(6 / chloropyridazin-3-yl)cyclopropane-1-carboxylate (Example VII) in 5 mL of DMF is added to the reaction mixture and stirred at RT for 1 h. The reaction mixture is quenched with cold NH4Cl / solution and it is extracted three times with EtOAc. The organic phase is dried over MgSO4 and concentrated in vacuo to give the ethyl ester intermediate. The residue is treated with MeOH and 200 mg (8.35 mmol) lithium hydroxide and 3 mL water are added. The reaction mixture is stirred overnight at RT and treated with 2 mL (8.00 mmol) 4N sodium hydroxide solution. It is stirred at 45° C. for 1 h while the THF is evaporated under reduced pressure. DIPE is slowly added to the reaction mixture and separated. The aqueous phase is diluted with NH4Cl solution, acidified with citric acid and extracted with EtOAc. The organic phase is dried over MgSO4, filtered through silica gel and boiled down to dryness in vacuum. The residue is purified by column chromatography (silica gel: eluent: DCM / MeOH=100 / 0→85 / 15) to give 845 mg of product. C 15 H 13 F2N3O3 (M = 321.3 g / mol) ESI-MS: 322 [M+H] + R t (HPLC): 0.81 min (Method B) The following compounds are prepared according to the above general procedure (Example VIII.1):

[0101] [ka]

[0102] Example IX 6-(4-Acetylpiperazin-1-yl)pyridine-3-carbonitrile

[0103] [ka]

[0104] A mixture of 250 mg (2.05 mmol) 6-fluoropyridine-3-carbonitrile, 315 mg (2.46 mmol) 1-acetylpiperazine and 705 μL (4.10 mmol) DIPEA in 3 mL DMSO is stirred at 80° C. for 45 min and quenched with semiconcentrated NaCl / solution. The aqueous phase is extracted with EtOAc. The combined organic phase is dried by PTK and concentrated in vacuo to give 420 mg of product. C 12 H 14 NO (M=230.3 g / mol) ESI-MS: 231 [M+H] + R t (HPLC): 0.72 min (Method A)

[0105] Example X Example X.1 4-(4-Acetyl-3,3-dimethylpiperazin-1-yl)benzonitrile

[0106] [ka]

[0107] Dissolve 800 mg (1.21 mmol) of 4-(3,3-dimethylpiperazin-1-yl)benzonitrile trifluoroacetic acid (Example V.6) in 3 mL of pyridine and add 2.00 mL (21.2 mmol) of acetic anhydride. Reflux the reaction mixture overnight and evaporate under reduced pressure. Take up the residue in saturated NaHCO3 solution and extract with EtOAc. Dry the organic layer, concentrate in vacuum and purify by column chromatography (silica gel; eluent: DCM / MeOH=98 / 2→9 / 1) to give 80 mg of product. C 15 H19 NO (M = 257.3 g / mol) ESI-MS: 258 [M+H] + R t (HPLC): 0.85 min (Method A) Following the general procedure above (Example X.1) the following compounds are prepared:

[0108] [ka]

[0109] Example XI 4-(2,2-Dimethylpiperazin-1-yl)benzonitrile

[0110] [ka]

[0111] A solution of 56.5 mg (0.47 mmol) of 4-fluorobenzonitrile (CAS No. 1194-02-1) and 100 mg (0.47 mmol) of tert-butyl 3,3-dimethylpiperazine-1-carboxylate (CAS No. 259808-67-8) in 3 mL of NMP is treated with 120 μL (0.71 mmol) of DIPEA and stirred at 190 °C under microwave irradiation for 7 h. The reaction mixture is diluted with water and EtOAc, the organic layer is separated and washed with saturated NaHCO3 solution. The organic layer is dried, filtered and reduced under reduced pressure to give 120 mg of product. C 13 H 17 N3 (M = 215.29 g / mol) ESI-MS: 216 [M+H] + R t (HPLC): 0.84 min (Method A)

[0112] Preparation of final compounds Example 1.1 N-(4-(7-acetyl-2,7-diazaspiro[3.5]nonan-2-yl)benzyl)-1-(6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide

[0113] [ka]

[0114] 300 mg (0.88 mmol) of 1-(6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)cyclopropane-1-carboxylic acid (Example VIII.2) and 0.45 mL (2.65 mmol) of DIPEA are diluted in 3 mL of DMF and 370 mg (0.97 mmol) of HATU are added. The mixture is stirred for 5 min at RT and then 242 mg (0.88 mmol) of 1-(2-(4-(aminomethyl)phenyl)-2,7-diazaspiro[3.5]nonan-7-yl)ethan-1-one (Example II.4) is added. The reaction mixture is stirred for 30 min at RT, diluted with MeOH and purified by HPLC to give the product. C 31 H 33 F3N6O3 (M = 594.6 g / mol) ESI-MS: 595 [M+H] + R t (HPLC): 0.96 min (Method A) 1H NMR (400 MHz, DMSO-d6) δ 8.90 (d, J=1.39 Hz, 1H), 8.20 (dd, J=1.46, 8.05 Hz, 1H), 7.91-7.99 (m, 2H), 7.61 (d, J=9.13 Hz, 1H), 7.27 (d, J=9.13 Hz, 1H), 7.02 (d, J=8.49 Hz, 2H), 6.35 (d, J=8.49 Hz, 2H), 5.67 (s, 2H), 4.13 (d, J=5.83 Hz, 2H), 3.54 (d, J=1.77 Hz, 4H), 3.40 (td, J=5.61, 14.38 Hz, 4H), 1.99 (s, 3H), 1.61-1.78 (m, 4H), 1.22-1.46 (m, 4H) The following compounds are prepared according to the above general procedure (Example 1.1):

[0115] [ka] TIFF0007617165000058.tif208163 TIFF0007617165000059.tif197163 TIFF0007617165000060.tif124159

[0116] [Table 12] TIFF0007617165000062.tif197146 TIFF0007617165000063.tif161145

[0117] [Table 13] TIFF0007617165000065.tif192147 TIFF0007617165000066.tif187147 TIFF0007617165000067.tif171146 TIFF0007617165000068.tif203147 TIFF0007617165000069.tif161146

[0118] Analytical HPLC Method A

Table 14

[0119] Method B

Table 15

[0120] Method C

Table 16

[0121] Method D

Table 17

[0122] Method E

Table 18

[0123] Method F

Table 19

[0124] Method G

Table 20

[0125] Method H

Table 21

[0126] Method I

Table 22

Claims

1. A compound of formula (I). 【Chemistry 1】 (I) (In the formula, A is fluoro and F 1-7 -Fluoro-C 1-3 -pyridyl substituted with one or two members of the group consisting of alkyl; E is fluoro and F 1-7 -Fluoro-C 1-3 - selected from the group consisting of phenyl and pyridyl, optionally substituted with one or two members of the group consisting of alkyl; K is the following group 【Chemistry 2】 selected from the group consisting of: R 3 is R 4 (O)C-, methyl, and 【Chemistry 3】 ; selected from the group consisting of: R 4 is methyl.)

2. A is 1 or 2 F 1-3 -Fluoro-C 1 2. The compound of formula (I) according to claim 1, which is pyridyl substituted with -alkyl.

3. A is the following group 【Chemistry 4】 2. The compound of formula (I) according to claim 1, selected from the group consisting of:

4. E is F and F 3 A compound of formula (I) according to any one of claims 1 to 3, wherein the aryl group is selected from the group consisting of phenyl and pyridyl, optionally substituted with one or two members of the group consisting of C.

5. E is the following group 【Chemistry 5】 A compound of formula (I) according to any one of claims 1 to 3, selected from the group consisting of:

6. The following compound: 【Chemistry 6】 【Chemistry 7】 【Chemistry 8】 【Chemistry 9】 2. The compound of formula (I) according to claim 1, selected from the group consisting of:

7. A compound of the formula: 【Chemistry 10】

8. A compound of the formula: 【Chemistry 11】

9. A compound of the formula: 【Chemistry 12】

10. A compound of the formula: 【Chemistry 13】

11. A compound of the formula: 【Chemistry 14】

12. A compound of the formula: 【Chemistry 15】

13. A compound of the formula: 【Chemistry 16】

14. A compound of the formula: 【Chemistry 17】

15. A compound of the formula: 【Chemistry 18】

16. A compound of the formula: 【Chemistry 19】

17. A salt, particularly a pharma- ceutically acceptable salt, of a compound according to any one of claims 6 to 16.

18. A pharmaceutical composition comprising at least one compound of formula (I) according to any one of claims 1 to 16 or a pharma- ceutically acceptable salt thereof, or at least one salt according to claim 17, and one or more pharma- ceutically acceptable excipients.

19. 19. A pharmaceutical composition according to claim 18 for the treatment or prevention of an inflammatory airway disease or a fibrotic disease.

20. 19. The pharmaceutical composition according to claim 18 for the treatment or prevention of idiopathic pulmonary disease (IPF) or systemic sclerosis (SSc).

Images